

1 **Title:** Prevalence of severe adverse events in health professionals after
2 receiving the first dose of the COVID-19 vaccination in Togo, March
3 2021.

4 **Short title:** Prevalence of severe adverse events in health professionals
5 after the COVID-19 vaccination in Togo, 2021.

6 **Authors:**

7 Yao Rodion KONU ^{1,2}, Fifonsi Adjidossi GBEASOR-KOMLANVI ^{1,2}, Mouhoudine
8 YERIMA ³, Arnold Junior SADIO ^{1,2}, Martin Kouame TCHANKONI ², Wendpouire Ida
9 Carine ZIDA-COMPAORE ², Josée NAYO-APETSIANYI ⁴, Kossivi Agbélénbko
10 AFANVI ^{1,4}, Sibabe AGORO ^{1,4}, Mounerou SALOU ⁵, Dadja Essoya LANDOH ⁶,
11 Atany B. NYANSA ³, Essohanam BOKO⁷, Moustafa MIJIYAWA ^{4,7}, Didier Koumavi
12 EKOUEVI ^{1,2,8} #

- 13 1. Université de Lomé, Département de Santé Publique, Lomé, Togo
14 2. Centre Africain de Recherche en Epidémiologie et en Santé Publique
15 (CARESP), Lomé, Togo
16 3. Ministère de la Santé et de l'Hygiène Publique, Service de pharmacovigilance
17 Lomé, Togo
18 4. Ministère de la Santé et de l'Hygiène Publique, Lomé, Togo
19 5. Université de Lomé, Laboratoire de Biologie Moléculaire et d'Immunologie
20 (BIOLIM), Lomé Togo
21 6. World Health Organization (WHO), Country Office of Togo, Lomé, Togo
22 7. Université de Lomé, Faculté des Sciences de la Santé, Lomé, Togo
23 8. Centre Inserm, 1219, Institut de Santé Publique et de Développement et
24 Université de Bordeaux, Bordeaux, France
25

26 **Corresponding author #**

27 Didier Koumavi EKOUEVI
28 Université de Lomé
29 Cell : 00228 9313 6655
30 Mail : didier.ekouevi@gmail.com
31

32

33 **Abstract:**

34 **Introduction:** Covid-19 vaccines can cause adverse events (AE) that can lead to
35 increased hesitation or fear of vaccination. This study aims at estimating the
36 prevalence of severe adverse events (SAEs) and their associated factors among
37 health professionals (HPs) vaccinated with COVISHIELD™ vaccine in Togo.

38 **Methods:** A cross-sectional study was conducted from March 13th to 19th, 2021 in Togo
39 among HPs who received the first dose of vaccine. An online self-administered
40 questionnaire was used to collect data on sociodemographic characteristics and
41 vaccination. SAEs were defined as one resulting in hospitalization, medical
42 consultation, or inability to work the day following the administration of the vaccine.
43 Regression analysis were performed to assess factors associated with SAEs.

44 **Results:** A total of 1,639 HP (70.2% male) with a median age [IQR] of 32 years [27-
45 40] participated. At least one AE was reported among 71.6% (95%CI= [69.3-73.8]).
46 The most commonly reported AEs were pain at the injection site (91.0%), asthenia
47 (74.3%), headache (68.7%), soreness (55.0%), and fever (47.5%). An increased libido
48 was also reported in 3.0% of HP. Among HP who experienced AEs, 18.2% were unable
49 to go to work the day after vaccination, 10.5% consulted a medical doctor, and 1.0%
50 were hospitalized. The SAE prevalence was 23.8% (95%CI= [21.8-25.9]). Being <30
51 years (aOR=5.54; p<0.001), or 30-49 years (aOR=3.62; p<0.001) and being female
52 (aOR=1.97; p<0.001) were associated with SAEs.

53 **Conclusion:** Despite the occurrence of SAEs, current data collected in Togo about
54 adverse events are reassuring with COVISHIELD™ vaccine and how they could be
55 managed.

56 **Keywords:** Severe adverse event, COVID-19, vaccine, prevalence, health
57 professionals, Togo.

58

59 **Key points:**

- 60
- The prevalence of severe adverse events (SAEs) after COVID-19 vaccination
61 was high among health professionals in Togo, especially in the youths (under
62 30years).
 - Despite the occurrence of SAEs, current data collected in Togo about adverse
63 events are reassuring with COVISHIELD(TM) vaccine and provide information
64 about how the could be managed.
65
- 66
- 67
- 68

69 **1. Introduction**

70 Coronavirus disease 2019 (COVID-19) was first described in China in December 2019
71 [1] and resulted in the declaration of a pandemic in January 2020 [2]. As of March 24,
72 2021, more than 120 million cases of COVID-19 infections, with more than 2 million
73 deaths, were reported worldwide [3].

74 No cure or vaccine was available until December 2020. Therefore, controlling the
75 infection to prevent the spread of COVID-19 was considered the only intervention [4].
76 Several social and public health risk mitigation measures were proposed and
77 implemented to reduce the spread of the pandemic. These measures include individual
78 measures (frequent hand hygiene, physical distancing, and use of masks) and physical
79 and social distancing measures (reduction of mass gatherings, and promotion of
80 telecommuting) [5].

81 However, given that vaccination has been identified as a relevant intervention for
82 stopping epidemics and fighting against infectious diseases, research on a COVID-19
83 vaccine has been promoted. At an early stage of this pandemic, the World Health
84 Organization (WHO) and the Global Alliance for Vaccines and Immunization (Gavi)
85 launched a pooled procurement mechanism for new COVID-19 vaccines called the
86 COVAX Facility to ensure fair, global and equitable access to vaccines [6]. This facility
87 also aims to end the acute phase of the COVID-19 pandemic by accelerating the
88 development of safe and effective vaccines against COVID-19 and contributing to the
89 development of production capacity [7]. The first vaccines received the Emergency
90 Use Listing from WHO in December 2020 [8].

91 Like many African countries, Togo has joined the COVAX facility and participated in
92 COVID-19 vaccine procurement process [6]. On March 7, 2021, Togo received the first

93 allocation of 156,000 doses of the SII-AstraZeneca (COVISHIELD™) vaccine [9].
94 COVISHIELD™ was developed by AstraZeneca and Oxford University and produced
95 by the Pune-based Serum Institute of India [10]. It is a viral vector vaccine (ChAdOx1-
96 S) that was approved for emergency use by the WHO [11]. In Togo, the vaccination
97 campaign was launched on March 10th, 2021. According to the National Deployment
98 and Vaccination Plan for COVID-19 vaccines, the priority target was 35,119 health
99 professionals (HP) followed by people over 50 years of age and those living with at
100 least one comorbidity condition (hypertension, diabetes, heart disease etc.) [12]. These
101 groups were targeted because they are at greater risk of exposure to COVID-19 or
102 because they have an increased risk of death in case of infection.

103 Vaccination against COVID-19 is an essential pillar for controlling the pandemic in
104 addition to other infection risk mitigation measures included in test, treat, track (T3)
105 approach. In Togo, vaccination against COVID-19 is implemented at a time when the
106 country is experiencing an epidemic peak with more than 600 cases per week since
107 February 1st, 2021 compared to 100 cases per week in December 2020 [13]. As of
108 March 24th, 2021, 9147 COVID-19 infections cases, of which, 105 deaths, have been
109 reported in Togo [14].

110 Despite the awareness campaign on the importance of vaccination, several factors
111 contribute to limiting the adherence of the population to this intervention. These
112 include: i) the relative speed of discovery and availability the of vaccines, ii) the use of
113 new technologies never before deployed in humans, and iii) the lack of hindsight
114 regarding the safety of vaccines that are available.

115 As a result, false information has been circulating about these new vaccines and has
116 contributed to the growing anxiety and vaccine hesitancy associated with a fear of

117 occurrence of long-term adverse events. In addition, the suspension of the
118 AstraZeneca vaccine in Europe after the occurrence of thrombosis cases has amplified
119 psychosis with popular pressure to stop the vaccination campaign in Africa including
120 Togo.

121 On March 11 and 12, Togo conducted a large-scale vaccination program against
122 COVID-19 for HP and 18,249 were vaccinated [15]. In parallel with the surveillance of
123 adverse events following immunization which is ensured by the pharmacovigilance
124 service of the Ministry of Health, this study was launched to quickly document adverse
125 events to reassure the population. Our objective was to estimate the prevalence of
126 severe adverse events (SAEs) and their associated factors among HPs in Togo.

127

128 **2. Methods**

129 ***2.1. Study design and setting***

130 This study was a cross-sectional study that was conducted from March 13 to 19, 2021
131 in Togo.

132 Togo is a country of West Africa that covers an area of 56,800 km² with an average
133 density of 145 inhabitants per square kilometer [16]. The population was 8.08 million
134 in 2019, of which 50.2% were women [17]. Most of the population is young (60% of
135 Togolese are under 25 years of age), and lives in rural areas (62%) [17]. Togo's health
136 system has a three-level pyramid structure: central, intermediate and peripheral levels.
137 Administrative and healthcare delivery components are associated with every level.

138 ***2.2. Study population and sample size***

139 The target population included all HPs who received the first dose of the
140 COVISHIELD™ vaccine during the first phase of the vaccination campaign in Togo.
141 For the purpose of this study, a health professional was defined as a professional who
142 works or is affiliated with the health sector, including workers from health administration
143 and logistics, clinical settings, and community health workers. The inclusion criteria for
144 eligible participants were: (i) being a health professional aged 18 years and older; and
145 (ii) having received the first dose of vaccine.

146 The sample size of participants was calculated using a single proportion population
147 formula with a 95% confidence level. In the absence of previous studies on the severity
148 of the adverse events of the vaccine against COVID-19, we hypothesized that 10% of
149 the participants would experience at least one severe adverse event with a 2% margin

150 error and a 10% nonresponse rate. The minimum number of participants was
151 estimated at 960.

152 ***2.3. Data collection***

153 A multiple-choice questionnaire was developed using items from a questionnaire of the
154 Pharmacovigilance Department of the Togo Ministry of Health and from previous
155 related studies found in the literature [18,19]. The questionnaire consisted of two main
156 sections on sociodemographic and professional characteristics (age, sex, marital
157 status, working place) and vaccination (date, process, confidence in the vaccine
158 efficacy, occurrence of adverse events and likelihood of getting the second dose). The
159 self-administered questionnaire was made available using a free online platform
160 through the internal communication networks of the Ministry of Health. The data
161 collection process began two days after the end of the first phase of the vaccine
162 campaign which targeted HPs in Togo.

163 ***2.4. Definition of the outcome variable***

164 The main outcome was the severity of reported adverse events. Adverse events were
165 grouped into three categories: severe (presence of adverse events resulting in self-
166 reported hospitalization, seeking medical consultation, and inability to work the day
167 following the administration of the vaccine), moderate (presence of adverse events
168 without hospitalization, consultation or impact on working ability), and no side effects.

169 ***2.5. Data management and statistical analysis***

170 Data were imported into a Microsoft Excel database for data cleaning. Descriptive
171 statistics were performed, and the results are presented using frequency tabulations
172 and percentages for categorical variables. Quantitative variables are presented as

173 medians with their interquartile range (IQR). Proportions were compared using Chi-
174 square test or Fisher's exact test when appropriate. Prevalence of SAEs was estimated
175 with its 95% confidence interval (95% CI).

176 Univariable and multivariable logistic model regression were performed to assess
177 factors associated with SAEs. For model building, characteristics that had a p-value
178 <0.20 in univariable analysis were considered for the full multivariable models, which
179 were subsequently finalized using a stepwise, backward elimination approach (p-value
180 <0.05). Predictor variables were selected as those found to be relevant according to
181 the literature review. Sensitivity analysis was performed based on a second definition
182 of SAEs which considered only self-reported hospitalization or seeking medical
183 consultation. Data analysis were performed using R[®] version 4.0.1 software, and the
184 level of significance was set at 5%.

185 ***2.6. Ethical considerations***

186 Ethical approval was obtained from the 'Comité de Bioéthique de Recherche en Santé'
187 (Bioethics Committee for Health Research) from the Togo Ministry of Health (No.
188 01/2021/CBRS). An introductory question was asked to ensure participants' consent.

189

190 **3. Results**

191 **3.1. Sociodemographic characteristics of health professionals**

192 A total of 1,639 HPs (70.2% male) who had received the first dose of the vaccine
193 responded to the questionnaire. This sample represents 4.6% of the HPs vaccinated
194 in Togo.

195 The median age [IQR] of the participants was 32 years [27-40]. Approximately half
196 (45.8%) of the participants resided or practiced in the *Grand-Lomé* region and 54.7%
197 were married (Table 1).

198 **3.2. Prevalence of adverse events**

199 Among the 1,639 participants, 1174 (71.6%, 95% CI = [69.3-73.8]) reported at least
200 one side effect. The most commonly reported adverse events were pain at the injection
201 site (91.0%), asthenia (74.3%), headache (68.7%), body aches (55.0%), and fever
202 (47.5%). An increase in libido was also reported in 3.0% of the participants (Figure 1).
203 Of the participants who experienced adverse events, 18.2% were unable to go to work
204 the day after vaccination, 10.5% consulted a medical doctor, and 1.0% were
205 hospitalized. Thus, the prevalence of SAEs was 23.8% (95% CI = [21.8-25.9]).

206 **3.3. Post vaccination treatment**

207 Overall, medication use after vaccination was higher among participants with SAEs
208 ($p < 0.001$). The use of analgesics by participants with SAE was 62.3% vs 39.0% for
209 participants with moderate events and 5.2% for those reporting no events (Table 2).

210 **3.4. Perception after vaccination**

211 A total of 67.5% of survey participants expressed concern about long-term adverse
212 events, and this concern was more pronounced among women than men (74.2% vs.
213 64.7%, $p < 0.001$). Approximately one out of ten participants (10.9%) said they were not
214 ready to take the second dose of the vaccine (Table 3).

215 ***3.5. Factors associated with the occurrence of severe adverse events***

216 In univariate analysis, factors associated with the occurrence of SAEs included being
217 under 30 years of age (OR=4.74; $p < 0.001$), or 30-49 years of age (OR=3.00; $p < 0.001$)
218 and being female (OR=2.07; $p < 0.001$). The same factors were associated with the
219 occurrence of SAEs in multivariate analysis (Table 4).

220 Using the second definition of SAEs, the prevalence of SAEs was estimated at 10.6%
221 (95% CI = [9.2-12.2]); the factors associated with the occurrence of SAE were the
222 same both in univariate and in multivariate analysis (under 30 years of age aOR=2.23;
223 $p = 0.049$; 30-49 years of age, aOR=2.73, $p = 0.016$ and being female, aOR=2.01,
224 $p < 0.001$).

225

226

227 **4. Discussion**

228 This is the first study in Africa to report SAEs after vaccination with the COVISHIELD™
229 vaccine in the context of COVID-19 among HPs. We included 4.6% of healthcare
230 professionals vaccinated in Togo. SAEs were reported among 23.8% of participants in
231 the current study. Most adverse events reported were mild or severe and compared
232 with those reported in trials of AstraZeneca [20,21]. However, this study clearly shows
233 that the odds of experiencing SAEs after vaccination against COVID-19 are higher in
234 younger people and women compared to older adults and men, respectively.

235 Based on our operational definition, approximately one-quarter of participants reported
236 SAEs. This value could be overestimated since because we included the inability to
237 work the day after vaccination. If we consider only hospitalization and consultation of
238 a medical doctor after vaccination, approximately 12.0% presented SAEs. In a single-
239 blind, randomized, controlled, phase 2/3 trial (COV002), in the United Kingdom (UK),
240 as of October 26, 2020, 13 serious adverse events occurred during the study period,
241 but none of those were considered to be related to the study vaccine [22]. The interim
242 analysis of the efficacy and safety of the ChAdOx1 nCoV-19 vaccine includes data
243 from four ongoing blinded, randomized, controlled trials performed across three
244 countries including the UK, Brazil and South Africa, and was reported in January 2021
245 [20]. In this analysis, 175 SAEs occurred in 168 participants, of which three events
246 were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group,
247 one in the control group, and one in a participant who remained masked to group
248 allocation.

249 Several definitions exist to classify adverse events according to their severity. For
250 example, in the COV002 trial, in the UK, SAEs were defined as substantial limitations
251 in activity and medical intervention or the requirement of therapy [22].

252 We did not include, the use of medication in our definition, given that the study
253 population was included HPs who have easy access to medication and a proven
254 tendency to self-medicate [23,24]. Interpretations of the severity of adverse events
255 must take into account the definition we adopted.

256 In our study, SAEs were more common in younger people than in people aged 50
257 years and older. The younger the subject was, the more severe the adverse events
258 tended to be. This trend has been reported by Oxford COVID Vaccine Trial Group and
259 seems to be related to an exaggerated immune response in young subjects [22]. In
260 other countries, severe events following the COVISHIELD™ vaccine have been
261 observed more in subjects under 55 years of age, which has prompted France among
262 other countries to exclusively recommend this vaccine for subjects aged 55 years and
263 older. In Togo, such recommendation is difficult to apply given there is no other vaccine
264 available to date.

265 Adverse events after vaccination were more pronounced in women. This observation
266 is not unusual for vaccines in general [25] and seems to be consistent with data in the
267 literature about COVID-19 vaccines [26,27]. More SAEs in women have been reported
268 in other settings and appear to be related to a stronger immune response triggered by
269 estrogen [25].

270 Most reported adverse events with the COVID-19 vaccine were mild. A sore arm was
271 the most common, and others included headache, tiredness, and a mild flu-like
272 symptoms [28,29]. Similar adverse events were reported in our study. However, in our

273 study, an increase in libido was unexpectedly reported by 3.0% of HPs in both men
274 and women. Among all UK spontaneous reports received between March 4,2021 and
275 March 14,2021 for COVID-19 Oxford University/AstraZeneca vaccine, one case of
276 increased libido, one of decreased libido and six cases of loss of libido were mentioned
277 [30]. This information should be investigated to demonstrate an association with
278 vaccination.

279 Concerning the perception/intention after the first dose of vaccine, two thirds of the
280 participants expressed concern about long-term adverse events, and one out of ten
281 declared they were not ready to take the second dose of the vaccine. These results
282 could be explained by several concerns about ChAdOx1 nCoV-19 which arose in
283 Europe and some African countries and resulted in the temporarily suspension the
284 administration of this vaccine [31].

285 This study presents some limitations. We cannot exclude selection bias due to our
286 sampling method. Another limitation is that data collection was based on a declarative
287 approach. However, given that the participants were HPs, the reported effects are
288 probably consistent with reality.

289 Finally, we used an operational definition to define SAE. This is a composite variable
290 including absence from work the day after vaccination, medical consultation and
291 hospitalization due to adverse events. This definition probably led to an overestimation
292 of SAE, but this operational definition seems appropriate in the Togolese context.

293 Based on these results of a high prevalence of SAEs in young people, systematic
294 prescription of antalgics or antipyretics could be proposed to young people who are
295 eligible to be vaccinated. Careful monitoring of SAEs should be performed in younger

296 people under 50 years of age. If another vaccine becomes available in Togo, the
297 COVISHIELD™ vaccine should be reserved for older adults.

298 A cohort study is therefore needed for a follow-up of HPs to better document the
299 occurrence of long-term adverse events. The results from the present study are useful
300 for designing a sensitization program in order to reassure the general population about
301 COVID-19 vaccination. At this stage, there is no reported sign in link with thrombosis.

302 5. **Conclusion**

303 In conclusion, despite the occurrence of SAEs, vaccination against COVID-19 remains
304 an important strategy to fight against this pandemic. Current data collected in Togo are
305 reassuring about adverse events and how they could be managed.

306

307 **Declarations:**

- 308 i. **Funding:** Not applicable
- 309 ii. **Conflicts of interest/Competing interests:** The authors declare that they have
310 no competing interests. DEL works for the World Health Organization, Togo
311 country office. The authors are solely responsible for the views expressed in
312 this manuscript and do not necessarily represent the decisions, policies or views
313 of the World Health Organization.
- 314 iii. **Availability of data and material:** Available on request to the corresponding
315 author.
- 316 iv. **Code availability:** Not applicable
- 317 v. **Ethics approval:** This study obtained ethical approval from the 'Comité de
318 Bioéthique de Recherche en Santé' (Bioethics Committee for Health Research)
319 from the Togo Ministry of Health (No. 01/2021/CBRS).
- 320 vi. **Consent to participate:** informed consent was collected prior to inclusion.
- 321 vii. **Consent for publication:** Not applicable

322

323 **References**

- 324 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus
325 from Patients with Pneumonia in China, 2019. *N Engl J Med.* 2020 Feb
326 20;382(8):727–33.
- 327 2. World Health Organization (WHO). Statement on the second meeting of the
328 International Health Regulations (2005) Emergency Committee regarding the
329 outbreak of novel coronavirus (2019-nCoV) [Internet]. [cited 2021 Mar 29].
330 Available from: [https://www.who.int/news/item/30-01-2020-statement-on-the-](https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))
331 [second-meeting-of-the-international-health-regulations-\(2005\)-emergency-](https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))
332 [committee-regarding-the-outbreak-of-novel-coronavirus-\(2019-ncov\).](https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov))
- 333 3. World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard
334 [Internet]. [cited 2021 Mar 24]. Available from: <https://covid19.who.int>
- 335 4. Bruinen de Bruin Y, Lequarre A-S, McCourt J, Clevestig P, Pigazzani F, Zare
336 Jeddi M, et al. Initial impacts of global risk mitigation measures taken during the
337 combatting of the COVID-19 pandemic. *Saf Sci.* 2020 Aug;128:104773.
- 338 5. World Health Organization (WHO). Overview of Public Health and Social
339 Measures in the context of COVID-19 [Internet]. [cited 2020 Jun 19]. Available
340 from: [https://www.who.int/publications-detail-redirect/overview-of-public-health-](https://www.who.int/publications-detail-redirect/overview-of-public-health-and-social-measures-in-the-context-of-covid-19)
341 [and-social-measures-in-the-context-of-covid-19.](https://www.who.int/publications-detail-redirect/overview-of-public-health-and-social-measures-in-the-context-of-covid-19)
- 342 6. 172 countries and multiple candidate vaccines engaged in COVID-19 vaccine
343 Global Access Facility [Internet]. [cited 2021 Mar 24]. Available from:
344 [https://www.who.int/news/item/24-08-2020-172-countries-and-multiple-](https://www.who.int/news/item/24-08-2020-172-countries-and-multiple-candidate-vaccines-engaged-in-covid-19-vaccine-global-access-facility)
345 [candidate-vaccines-engaged-in-covid-19-vaccine-global-access-facility](https://www.who.int/news/item/24-08-2020-172-countries-and-multiple-candidate-vaccines-engaged-in-covid-19-vaccine-global-access-facility)
- 346 7. World Health Organization (WHO). COVID-19 vaccines [Internet]. [cited 2021
347 Mar 24]. Available from: [https://www.who.int/emergencies/diseases/novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines)
348 [coronavirus-2019/covid-19-vaccines](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines)
- 349 8. World Health Organization (WHO). WHO issues its first emergency use
350 validation for a COVID-19 vaccine and emphasizes need for equitable global
351 access [Internet]. [cited 2021 Mar 26]. Available from:
352 [https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-](https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access)
353 [validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-](https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access)
354 [access](https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access)
- 355 9. Global Alliance for Vaccination and Immunization (GAVI). COVAX roll-out -
356 Togo [Internet]. [cited 2021 Mar 24]. Available from: [https://www.gavi.org/covax-](https://www.gavi.org/covax-vaccine-roll-out/togo)
357 [vaccine-roll-out/togo](https://www.gavi.org/covax-vaccine-roll-out/togo)
- 358 10. Staff S. Covid-19: India looking at all ‘serious’ side effects amid safety concerns
359 about AstraZeneca vaccine [Internet]. *Scroll.in.* <https://scroll.in>; [cited 2021 Mar
360 26]. Available from: [https://scroll.in/latest/989440/covid-19-india-looking-at-all-](https://scroll.in/latest/989440/covid-19-india-looking-at-all-serious-side-effects-amid-safety-concerns-about-astrazeneca-vaccine)
361 [serious-side-effects-amid-safety-concerns-about-astrazeneca-vaccine](https://scroll.in/latest/989440/covid-19-india-looking-at-all-serious-side-effects-amid-safety-concerns-about-astrazeneca-vaccine)


- 362 11. World Health Organization (WHO). WHO recommendation Serum Institute of
363 India Pvt Ltd - COVID-19 Vaccine (ChAdOx1-S [recombinant]) - COVISHIELD™
364 [Internet]. WHO - Prequalification of Medical Products (IVDs, Medicines,
365 Vaccines and Immunization Devices, Vector Control). 2021 [cited 2021 Mar 26].
366 Available from: [https://extranet.who.int/pqweb/vaccines/covid-19-vaccine-](https://extranet.who.int/pqweb/vaccines/covid-19-vaccine-chadox1-s-recombinant-covishield)
367 [chadox1-s-recombinant-covishield](https://extranet.who.int/pqweb/vaccines/covid-19-vaccine-chadox1-s-recombinant-covishield)
- 368 12. COVID-19 national deployment and vaccination plan: Submission and review
369 process, 29 January 2021 [Internet]. [cited 2021 Mar 30]. Available from:
370 [https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-NDVP-](https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-NDVP-country_plans-2021.1)
371 [country_plans-2021.1](https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-NDVP-country_plans-2021.1)
- 372 13. République Togolaise, Ministère de la Santé, de l'Hygiène Publique et de
373 l'Accès Universel aux Soins. Epidémie de COVID-19 au Togo-Rapport de
374 situation N°381 au 28 mars 2021. 2021; 10p.
- 375 14. République Togolaise. COVID-19 [Internet]. COVID 19. [cited 2021 Mar 24].
376 Available from: <https://covid19.gouv.tg/>
- 377 15. République Togolaise. Ministère de santé, de l'hygiène publique et de l'accès
378 universel aux soins. Vaccination du personnel de santé du pays contre la
379 COVID-19 (Bulletin d'information N°2). 2021. 4p.
- 380 16. World Bank, Data Bank. CountryProfile [Internet]. [cited 2021 Mar 26]. Available
381 from:
382 [https://databank.worldbank.org/views/reports/reportwidget.aspx?Report_Name=](https://databank.worldbank.org/views/reports/reportwidget.aspx?Report_Name=CountryProfile&Id=b450fd57&tbar=y&dd=y&inf=n&zm=n&country=TGO)
383 [CountryProfile&Id=b450fd57&tbar=y&dd=y&inf=n&zm=n&country=TGO](https://databank.worldbank.org/views/reports/reportwidget.aspx?Report_Name=CountryProfile&Id=b450fd57&tbar=y&dd=y&inf=n&zm=n&country=TGO)
- 384 17. République Togolaise, Direction Générale de la Statistique et de la Comptabilité
385 Nationale du Togo (DGSCN). Résultats définitifs du 4ième Recensement
386 Général de la Population et de l'Habitat (4ième RGPH4). Lomé : DGSCN ; 2010,
387 66p. Disponible sur : <https://inseed.tg/download/2958/>.
- 388 18. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines:
389 comparison of biological, pharmacological characteristics and adverse effects of
390 Pfizer/BioNTech and Moderna Vaccines. *Eur Rev Med Pharmacol Sci*. 2021
391 Feb;25(3):1663–9.
- 392 19. D'Alessandro D, Ciriminna S, Rossini A, Bossa MC, Fara GM. Requests of
393 medical examinations after pneumococcal & influenza vaccination in the elderly.
394 *Indian J Med Res*. 2004 May;119 Suppl:108–14.
- 395 20. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al.
396 Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against
397 SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil,
398 South Africa, and the UK. *Lancet Lond Engl*. 2021;397(10269):99–111.
- 399 21. Torjesen I. Covid-19: First UK vaccine safety data are “reassuring,” says
400 regulator. *BMJ*. 2021 Feb 8;372:n363.

- 401 22. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens
402 DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine
403 administered in a prime-boost regimen in young and old adults (COV002): a
404 single-blind, randomised, controlled, phase 2/3 trial. *Lancet Lond Engl*.
405 2021;396(10267):1979–93.
- 406 23. Ran L, Chen X, Wang Y, Wu W, Zhang L, Tan X. Risk Factors of Healthcare
407 Workers With Coronavirus Disease 2019: A Retrospective Cohort Study in a
408 Designated Hospital of Wuhan in China. *Clin Infect Dis Off Publ Infect Dis Soc*
409 *Am*. 2020 Nov 19;71(16):2218–21.
- 410 24. Sadio AJ, Gbeasor-Komlanvi FA, Konu RY, Bakoubayi AW, Tchankoni MK,
411 Bitty-Anderson AM, et al. Assessment of self-medication practices in the context
412 of the COVID-19 outbreak in Togo. *BMC Public Health*. 2021 Jan 6;21(1):58.
- 413 25. Potluri T, Fink AL, Sylvia KE, Dhakal S, Vermillion MS, vom Steeg L, et al. Age-
414 associated changes in the impact of sex steroids on influenza vaccine
415 responses in males and females. *Npj Vaccines*. 2019 Jul 12;4(1):1–12.
- 416 26. Gee J. First Month of COVID-19 Vaccine Safety Monitoring — United States,
417 December 14, 2020–January 13, 2021. *MMWR Morb Mortal Wkly Rep [Internet]*.
418 2021 [cited 2021 Mar 26];70. Available from:
419 <https://www.cdc.gov/mmwr/volumes/70/wr/mm7008e3.htm>
- 420 27. Blumenthal KG, Robinson LB, Camargo CA, Shenoy ES, Banerji A, Landman
421 AB, et al. Acute Allergic Reactions to mRNA COVID-19 Vaccines. *JAMA*
422 [Internet]. 2021 Mar 8 [cited 2021 Mar 26]; Available from:
423 <https://jamanetwork.com/journals/jama/fullarticle/2777417>
- 424 28. World Health Organization (WHO). Coronavirus disease (COVID-19): Vaccines
425 safety [Internet]. [cited 2021 Mar 26]. Available from: [https://www.who.int/news-](https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines-safety)
426 [room/q-a-detail/coronavirus-disease-\(covid-19\)-vaccines-safety](https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines-safety)
- 427 29. US Centers for Diseases Control and Prevention (US CDC). What to Expect
428 after Getting a COVID-19 Vaccine [Internet]. Centers for Disease Control and
429 Prevention. 2021 [cited 2021 Mar 26]. Available from:
430 <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html>
- 431 30. Government of the United Kingdom. Assests publishing service. COVID-19
432 vaccine AstraZeneca analysis print. 2021. [Cited 26/03/2021]. Available from:
433 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/att](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/972833/COVID-19_AstraZeneca_Vaccine_Analysis_Print.pdf)
434 [achment_data/file/972833/COVID-19_AstraZeneca_Vaccine_Analysis_Print.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/972833/COVID-19_AstraZeneca_Vaccine_Analysis_Print.pdf).
- 435 31. World Health Organization (WHO). WHO statement on AstraZeneca COVID-19
436 vaccine safety signals [Internet]. [cited 2021 Mar 26]. Available from:
437 [https://www.who.int/news/item/17-03-2021-who-statement-on-astrazeneca-](https://www.who.int/news/item/17-03-2021-who-statement-on-astrazeneca-covid-19-vaccine-safety-signals)
438 [covid-19-vaccine-safety-signals](https://www.who.int/news/item/17-03-2021-who-statement-on-astrazeneca-covid-19-vaccine-safety-signals)

439

440

441
442
443



444
445
446
447
448

Figure 1. Proportion of adverse events among health professionals after vaccination against COVID-19, Togo, 2021 (n = 1,174)

Table 1. Sociodemographic characteristics of health professionals vaccinated against COVID-19 in Togo, 2021 (n = 1,639)

	Frequency	Proportion (%)
Age (years), Median (IQR)		32 (27-40)
Age (years)		
<30	634	38.7
30-49	862	52.6
≥50	143	8.7
Sex		
Female	488	29.8
Male	1151	70.2
Health region		
Grand-Lomé	751	45.8
Maritime	243	14.8
Plateaux	161	9.8
Centrale	104	6.4
Kara	274	16.7
Savanes	106	6.5
Marital status		
Single/Widowed/Divorced	742	45.3
Married	897	54.7

IQR: interquartile range

Table 2. Use of medication after vaccination against COVID-19 according to the severity of adverse events among health professionals, Togo, 2021

	Adverse events after COVID-19 vaccination				P
	None	Moderate	Severe	Overall	
	(n = 442)	(n = 807)	(n = 390)	(n = 1,639)	
Analgesics, n (%)	23 (5.2)	315 (39.0)	243 (62.3)	581 (35.4)	<0.001*
Antipyretics, n (%)	15 (3.4)	207 (25.7)	181 (46.4)	403 (24.6)	<0.001*
NSAIDs [§] , n (%)	10 (2.3)	82 (10.2)	65 (16.7)	157 (9.6)	<0.001*
Antihistamines, n (%)	1 (0.2)	23 (2.9)	43 (11.0)	67 (4.1)	<0.001**
Vitamin C, n (%)	1 (0.2)	19 (2.4)	17 (4.4)	37 (2.3)	<0.001**
Herbal medicines/infusions, n (%)	0 (0.0)	12 (1.5)	14 (3.6)	26 (1.6)	<0.001**

[§]NSAIDs: non-steroidal anti-inflammatory drugs

*Chi-squared test; **Fisher test

Table 3. Perceptions among health professionals after vaccination against COVID-19, Togo, 2021

	Female	Male	Overall	p
	(n = 488)	(n = 1,151)	(n = 1,639)	
Afraid of long-term adverse events				<0.001*
No	126 (25.8)	406 (35.3)	532 (32.5)	
Yes	362 (74.2)	745 (64.7)	1107 (67.5)	
Regret to have been vaccinated				<0.001*
No	347 (71.1)	923 (80.2)	1270 (77.5)	
Yes	141 (28.9)	228 (19.8)	369 (22.5)	
Ready for the second dose				0.004*
Hesitation	201 (41.2)	391 (34.0)	592 (36.1)	
No	59 (12.1)	119 (10.3)	178 (10.9)	
Yes	228 (46.7)	641 (55.7)	869 (53.0)	

*Chi-squared test

Table 4. Factors associated with severe adverse events after COVID-19 vaccination among health professionals in Togo, 2021

	Prevalence		Binary logistic model regression					
	n	%	Univariable			Multivariable		
			OR	95%CI	p	aOR	95%CI	p
Age (years)								
<30	192	30.3	4.74	2.67-9.22	<0.001	5.54	2.95-11.42	<0.001
30-49	186	21.6	3.00	1.69-5.83	<0.001	3.62	1.94-7.41	<0.001
≥50	12	8.4	1.00	-	-	1.00	-	-
Sex								
Female	164	33.6	2.07	1.63-2.63	<0.001	1.97	1.53-2.54	<0.001
Male	226	19.6	1.00	-	-	1.00	-	-
Having comorbidities								
Yes	55	21.9	0.88	0.63-1.21	0.447	1.12	0.70-1.73	0.628
No	335	24.1	1.00	-	-	1.00	-	-
History of COVID-19 infection								
No	339	23.6	1.07	0.64-1.88	0.815	0.98	0.57-1.75	0.934
No answer	9	36.0	1.94	0.72-5.08	0.182	1.90	0.69-5.08	0.206
Yes	18	22.5	1.00	-	-	1.00	-	-

OR: Odds ratio; aOR: adjusted Odds ratio; 95%CI: 95% confidence interval